Abstract:In recent years, with advancements in medicine, the survival period of patients with tumours has significantly increased. The adverse effects of tumour treatment on patients, especially cardiac toxicity, have become increasingly prominent. In elderly patients with breast cancer, treatment-related cardiovascular toxicity has surpassed cancer itself as the leading cause of death. Moreover, in recent years, an increasing number of novel antitumour drugs, such as multitargeted agents, antibody‒drug conjugates (ADCs), and immunotherapies, have been applied in clinical practice. The cardiotoxicity induced by these drugs has become more pronounced, leading to a complex and diverse mechanism of cardiac damage. The risks of unintended cardiovascular toxicity are increased by high-dose anthracyclines, immunotherapies, and concurrent radiation, in addition to traditional cardiovascular risk factors such as smoking, hypertension, diabetes, hyperlipidaemia, and obesity. However, these factors do not fully explain why only a subset of individuals experience treatment-related cardiac toxicity, whereas others with similar clinical features do not. Recent studies indicate that genetics play a significant role in susceptibility to the development of cardiovascular toxicity from cancer therapies. These genes are involved in drug metabolism, oxidative damage, cardiac dysfunction, and other processes. Moreover, emerging evidence suggests that epigenetics also plays a role in drug-induced cardiovascular toxicity. We conducted a review focusing on breast cancer as an example to help oncologists and cardiologists better understand the mechanisms and effects of genetic factors on cardiac toxicity. In this review, we specifically address the relationship between genetic alterations and cardiac toxicity, including chemotherapy-related genetic changes, targeted therapy-related genetic changes, and immune therapy-related genetic changes. We also discuss the role of epigenetic factors in cardiac toxicity. We hope that this review will improve the risk stratification of patients and enable therapeutic interventions that mitigate these unintended adverse consequences of life-saving cancer treatments.

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity

Anthracycline Cardiotoxicity: From Mechanisms to Prevention Strategies

Genetics of Anthracycline-Associated Cardiotoxicity

A Review on Anthracycline Induced Cardiotoxicity- A Mechanism-based Approach

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Anthracycline-induced cardiotoxicity: An overview from cellular structural perspective

[Cardiotoxicity of drugs used in oncology]

Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity

Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer

Genetic factors in the pathogenesis of cardio-oncology

Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients

Development of a Dose-Adjusted Polygenic Risk Model for Anthracycline-Induced Cardiotoxicity

Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions

Anthracycline Chemotherapy and Cardiotoxicity

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?

Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review

Epigenetic Mechanisms Involved in the Cardiovascular Toxicity of Anticancer Drugs

Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect

Review of potential predictors of anthracycline-induced cardiotoxicity from the position of disease pathogenesis

Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk